Takeda Highlights Pioglitazone Fracture Risk In “Dear Healthcare Provider” Letter
This article was originally published in The Pink Sheet Daily
FDA issues MedWatch alert March 9, the second time the agency has warned of fracture risk in women taking thiazolidinediones in recent weeks.
You may also be interested in...
FDA MedWatch alert issued Feb. 20 notes there were “significantly more” fractures in women taking rosiglitazone in the ADOPT trial.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.